The National Institute for Health and Care Excellence (NICE) has recommended Kesimpta (ofatumumab), which is a new treatment for people with multiple sclerosis (MS), to be prescribed on the NHS in England.
It can now be given to people with active relapsing remitting MS. Clinical trials compared Kesimpta with the drug Aubagio and found it reduces the risk of relapse by 50-59%.
Made by Novartis, Kesimpta works in a similar was to Ocrevus. It binds to the CD20 marker on the surface of B cells, which are thought to be involved in the immune system’s attack on myelin, and destroys them.
Kemimpta can be self-injected at home, weekly for three weeks, followed by monthly injections.
A decision from the Scottish Medicines Consortium is expected soon as to whether it is approved for use on the NHS north of the border.
Source: MS-UK 20 April 2021